22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the Cancer Epidemiology Biomarkers and Prevention (CEBP) journal has published a new independent study which found that using 22nd Century’s proprietary Very Low Nicotine tobacco cigarettes “may reduce harm exposure.” Further, “negative smoking behaviors do not increase, and exposure to nicotine and many toxic cigarette constituents likely decrease.” A group of eight researchers from the Center for Interdisciplinary Research on Nicotine Addiction at the University of Pennsylvania and the Masonic Cancer Center at the University of Minnesota conducted the r... [Read more]